MATTERHORN: Efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer - A randomized, double-blind, placebo-controlled, phase 3 study Meeting Abstract
| Authors: | Janjigian, Y.; Van Cutsem, E.; Muro, K.; Wainberg, Z.; Al-Batran, S. E.; Hyung, W. J.; Molena, D.; Evans, B.; Ruscica, D.; Robbins, S. H.; Negro, A.; Tabernero, J. |
| Abstract Title: | MATTERHORN: Efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer - A randomized, double-blind, placebo-controlled, phase 3 study |
| Meeting Title: | 2022 Deutscher Krebskongress. Krebsmedizin: Schnittstellen zwischen Innovation und Versorgung |
| Journal Title: | Oncology Research and Treatment |
| Volume: | 45 |
| Issue: | Suppl. 3 |
| Meeting Dates: | 2022 Nov 13-16 |
| Meeting Location: | Berlin, Germany |
| ISSN: | 2296-5270 |
| Publisher: | S. Karger AG |
| Date Published: | 2022-11-01 |
| Start Page: | 93 |
| Language: | English |
| ACCESSION: | WOS:000883051700219 |
| PROVIDER: | wos |
| DOI: | 10.1159/000521004 |
| Notes: | Meeting Abstract: 1044 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
